⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Daptomycin

داپتومایسین

⚠ Unverified

🦠 Antiinfectives For Systemic UseCyclic lipopeptide

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications ATC J01XX09

Market / country: 🇺🇸 USA

Cubicin (US)

🧮 Dose calculator

Disease / regimen

Skin and skin structure infection · Regimen source: FDA Cubicin RF · 2.2

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to daptomycin. FDA Cubicin RF · 4

Warnings

• Myopathy and rhabdomyolysis (weekly CPK); eosinophilic pneumonia; not effective for pneumonia; not under 1 y (muscular effects). FDA Cubicin RF · 5

Renal adjustment

• eGFR < 30: Adults CrCl <30 incl. dialysis: same mg/kg every 48 h (after dialysis). No paediatric renal adjustment established. FDA Cubicin RF · 2.6

Formulations

500 mg vial — powder for injection 🇺🇸 USA FDA Cubicin RF · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cubicin RF · 8.1
“Risk Summary Limited published data on use of CUBICIN RF in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cubicin RF · 8.2
“Risk Summary Limited published data report that daptomycin is present in human milk at infant doses of 0.1% of the maternal dose (see Data ) 2,3,4 .”
👶 ChildrenUse with caution
Label: established for cSSSI and S. aureus bacteraemia at 1–17 y; not under 1 y. FDA Cubicin RF · 8.4
“The safety and effectiveness of CUBICIN RF in the treatment of cSSSI and S. aureus bloodstream infections (bacteremia) have been established in the age groups 1 to 17 years of age.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cubicin RF · 8.5
“Of the 534 adult patients treated with CUBICIN in Phase 3 controlled clinical trials of complicated skin and skin structure infections (cSSSI), 27% were 65 years of age or older and 12% were 75 years of age or older.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)❌ None
DailyMed (FDA label)FDA Cubicin RF
MedlinePlus (NIH)Daptomycin Injection
WHO ATC/DDDJ01XX09
Darooyab (Iran)Daptomycin

🇮🇷 Not found in Iran list Darooyab · G-379/Daptomycin

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Cubicin RF · 3 FDA Cubicin RF · 2.2 FDA Cubicin RF · 2.4 FDA Cubicin RF · 2.3, Table 1 FDA Cubicin RF · 2.5, Table 2 FDA Cubicin RF · 4 FDA Cubicin RF · 5 FDA Cubicin RF · 2.6 FDA Cubicin RF · 8.1 FDA Cubicin RF · 8.2 FDA Cubicin RF · 8.4 FDA Cubicin RF · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-379/Daptomycin
Clinical review⚠ Unverified